T.he is a company The two most widely used covid-19 vaccines in America are at odds.Despite publicly promising not to enforce covid-19-related patents until the pandemic is over, American pharmaceutical company Moderna announced on Aug. filed lawsuits in American and German courts against RNA (mRNA) technique used by companies to make jabs. Another German pharmaceutical company, CureVac, also filed a lawsuit against BioNTech in July. The floodgates have opened for intellectual property disputes among vaccine makers.
The Covid-19 jab will soon be commercialized in the United States once the government is no longer the primary buyer and sales switch to the private sector, making patent ownership claims more pressing.Since the pandemic began The Jabmaker had postponed the lawsuit over concerns about its public image during the health crisis, despite widespread whispers about patent infringement. Last year, Moderna’s vaccine revenue hit his $18 billion mark, but Pfizer more than doubled his revenue.
Moderna claims Pfizer and BioNTech have copied a patented chemical modification that prevents destructive immune responses and the lipid shell used to obtain m.RNA jab into the cell. BioNTech says its work is original and will vigorously defend itself against all claims of patent infringement. Cases can be long and complicated.metersRNA A covid vaccine based on this technology has been developed very quickly thanks to the basic research of many scientists. With this collaborative approach it is impossible to identify a single inventor.
To further complicate matters, other scientists claim to fix the problem. Moderna is being sued by Canadian pharmaceutical company Arbutus over its lipid shell. Along with CureVac, smaller biotech companies such as his Allele and Alnylam in the US are suing Moderna and Pfizer over other parts of their vaccine technology. No doubt there will be more lawsuits in the future.
Moderna went to court because she had the most to lose.The future of the company rests on pharmaceuticals based on mRNA Technologies that could one day be used to treat diseases such as cancer HIVBut I’m stepping carefully. No injunction is being sought, so the Pfizer and Biontech vaccines will continue to be sold regardless of the outcome. But the lawsuit could set a precedent for how much of this kind of jointly developed technology is patentable.
Investors seem unfazed. Shares of Moderna, Pfizer and BioNTech have barely moved since the lawsuit was announced. Demand for vaccines is slowing, and investors are aware that long-running patent disputes are common in the pharmaceutical industry. Around the world, people are returning to the office in large numbers. Business as usual is back for an industry notorious for litigation.■
For more expert analysis of the biggest news in economics, business and markets, sign up for our weekly newsletter, Money Talks.
Comments
Post a Comment